52 Week Range
- Open Price
- Previous Close
Start SIP in BioconStart SIP
Biocon Investment Rating
Biocon (Nse) has an operating revenue of Rs. 11,174.20 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 10% is healthy, ROE of 2% is fair but needs improvement. The company has a debt to equity of 86%, which is bit higher. The stock from a technical standpoint is trading below to its 200DMA and around 5% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 28 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 138 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
|Indicator||Mar 2023||Dec 2022||Sep 2022||Jun 2022||Mar 2022|
|Oper Rev Qtr Cr||507||555||490||442||518|
|Operating Expenses Qtr Cr||551||518||462||439||491|
|Operating Profit Qtr Cr||-44||37||28||3||27|
|Depreciation Qtr Cr||29||29||30||29||28|
|Interest Qtr Cr||48||21||0||0||0|
|Tax Qtr Cr||-15||11||119||8||21|
|Net Profit Qtr Cr||1,811||35||988||15||38|
EMA & SMA
- Bullish Moving Average
- Bearish Moving Average
- 20 Day
- 50 Day
- 100 Day
- 200 Day
- 20 Day
- 50 Day
- 100 Day
- 200 Day
Biocon Resistance and Support
|MACD Single Line||2.82|
Biocon Delivery and Volume
|Period||NSE + BSE Volume Avg||NSE + BSE Delivery Volume Avg||NSE + BSE Delivery Volume %|
Biocon Result Highlights
NSE-Medical-Biomed/BiotechBiocon is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1992.90 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2023. Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417.
|Shares in Float||46.82|
|No of funds||286|
|U/D Vol ratio||1.3|
|LTDebt / Equity||12|
|Foreign Portfolio Investors||10.2%||14.42%||15.79%||16.31%|
|Financial Institutions/ Banks|
|Mr. Siddharth Mittal||Managing Director & CEO|
|Ms. Kiran Mazumdar Shaw||Executive Chairperson|
|Mr. John Shaw||Vice Chairman & Non Exe.Dire|
|Prof. Ravi Mazumdar||Non Executive Director|
|Mr. Mary Harney||Independent Director|
|Mr. Daniel M Bradbury||Independent Director|
|Dr. Vijay Kuchroo||Independent Director|
|Mr. M Damodaran||Independent Director|
|Mr. Bobby Kanubhai Parikh||Independent Director|
Biocon Corporate Action
|2023-05-23||Audited Results & Final Dividend|
|2023-04-26||Others||To consider, Fund Raising. per share(20%)Final Dividend|
|2023-07-07||FINAL||Rs.1.50 per share(30%)Final Dividend|
|2022-07-01||FINAL||Rs.0.50 per share(10%)Final Dividend|
What is Share Price of Biocon ?
Biocon share price is ₹243 As on 08 June, 2023 | 03:23
What is the Market Cap of Biocon ?
The Market Cap of Biocon is ₹29258.6 Cr As on 08 June, 2023 | 03:23
What is the P/E ratio of Biocon ?
The P/E ratio of Biocon is 63.2 As on 08 June, 2023 | 03:23
What is the PB ratio of Biocon ?
The PB ratio of Biocon is 1.3 As on 08 June, 2023 | 03:23
Is it a good time to invest in Biocon Limited?
Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.
How many times has Biocon Limited given dividends since 2004?
Biocon Ltd. has declared 17 dividends since July 1, 2004.
What is the stock price CAGR of Biocon Limited?
The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.
What is the debt-to-equity ratio of Biocon Limited?
The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.
What is the ROE of the Biocon Limited?
The ROE of Biocon Limited is 9% which is fair but needs improvement.
Who is the Managing Director of Biocon Limited?
Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.
Is Biocon a good stock to buy?
According to the record analysis of moneyworks4me, Biocom limited is an average quality company.
What is the revenue of Biocon?
The revenue of Biocon for FY22 is Rs. 8184 Cr.
How to buy shares of Biocon Ltd?
The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.